Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma

Abstract

Uterine serous carcinoma is a unique and biologically aggressive subtype of endometrial cancer and should be studied as a distinct entity. Futures studies should identify the optimized chemotherapy and radiation regimens, sequence of therapy and schedule, and the role of targeted biologic therapy.

Oncologic Safety of Laparoscopy in the Surgical Treatment of Type II Endometrial Cancer

“…Clear-cell carcinomas have absent reactivity for estrogen and progesterone receptors and low immunoreactivity for p53. 4 The absence of data specifically concerning utilization of laparoscopy in type II EC has motivated us to study the oncologic safety of the method.…”

“…It is responsible for approximately 40% of deaths related to EC, whereas it only accounts for 10% to 20% of cases. 4 Operative treatment for uterine malignancies has been historically performed via laparotomy. During the last decades, minimally invasive surgery has progressively gained more popularity in the surgical treatment of EC.…”

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up

“…Regarding non endometrioid tumour types, approximately 60–70% of patients with uterine serous cancer have disease outside the uterus at the time of presentation. The 5-year OS rate for patients with uterine serous cancer is 20–25% versus 80% for all patients with endometrial cancer 136. For these reasons, recommendations were made for the following subgroups: Endometrioid stage I, grade 3 and >50% myometrial invasion; endometrioid stage II; endometrioid stage III without residual disease and non-endometrioid tumour types.…”

“…However, a subgroup analysis of the NSGO 9501/EORTC 55991 and MaNGO-ILIADE III trials did not show a survival benefit for patients with serous or clear cell tumours 140. Given the high rates of distant metastasis observed in patients with uterine serous and clear cell tumours, adjuvant chemotherapy can be considered and clinical trials addressing these rare subtypes are encouraged 136,160. One retrospective study investigated the role of vaginal brachytherapy for stage I serous or clear cell cancers.…”

Változások a korai stádiumú operált méhtestcarcinoma sugárkezelésének indikációjában. Újabb stádiumbeosztás, prediktív tényezők. Tanulságok saját eredményeink alapján

“…A ≥50% nagyobb myometriuminvázió és grade 3 daganatok esetén (tekintet nélkül a nyirokcsomóstagingre) a becsült 5 éves teljes túlélés (OS) mindössze 58%. A nem endometrioid szö-vettani típusú méhtestdaganatos betegek 5 éves OS-érté-ke nagyon alacsony: körülbelül 20-25% versus 80% [19]. Emiatt ezt a csoportot négy további részre lehet osztani:…”